?? What a great session we had last week with Joseph Denby at NextGen Biomed by Oxford Global! If you missed his insightful talk, don’t worry — we’ve got you covered with some snapshots from the presentation. Joseph shared CPC Scientific Inc.’s expertise on "Green Approaches to Peptide API and Peptide-Oligonucleotide Conjugate (POC) Manufacturing," diving into sustainable practices that not only enhance efficiency but also ensure top-tier quality in peptide and POC production. Interested in the technical details or want to learn more? Don’t hesitate to reach out to us at [email protected] — we'd love to continue the conversation! #PeptideManufacturing #Sustainability #GreenChemistry #Innovation #API #POC #SustainableManufacturing #GMPPeptides #Peptide
关于我们
Founded in 2001, we are the third largest peptide-focused contract research, development, and manufacturing organization (“CRDMO”) worldwide in terms of sales revenue in 2023, according to Frost & Sullivan. We are also considered one of the most comprehensive peptide-focused CRDMO globally (Frost & Sullivan), offering complete life-cycle support from early-discovery, pre-clinical research and clinical development to commercial production. We mainly provide (i) contract research organization (“CRO”) services, including peptide new chemical entity (“NCE”) discovery synthesis; (ii) contract development and manufacturing organization (“CDMO”) services, including peptide chemistry, manufacturing, and controls (“CMC”) development; and (iii) contract manufacturing organization (“CMO”) services, including peptide NCE and generic drug commercial manufacturing. We have established global operations, with projects covering over 50 countries, including major markets in the United States, China, Japan, Europe, South Korea, and Australia. We also provide customers wit peptide drug development, production, and CMC filing support services that meet regulatory requirements in major markets worldwide. In addition to peptides, we have developed a diverse project pipeline focusing on various types of complex peptide- and oligonucleotide-based new chemical entities (“NCEs”). Our peptide conjugation services seamlessly integrate our peptide and oligonucleotide platforms to produce a wide range peptide conjugates products. The introduction of our PeptiConjuXTM and PeptiNuclide LinkTechTM are dedicated to the development and large-scale manufacturing (i.e., kilogram-scale) of peptide-oligonucleotide conjugates (“POC”), peptide drug conjugates (“PDC”), and radionuclide drug conjugates (“RDC”). As of December 31, 2023, we had successfully synthesized approximately 1,800 molecules through these two platforms.
- 网站
-
https://cpcscientific.com
CPC Scientific Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Rocklin，California
- 类型
- 上市公司
- 创立
- 2001
- 领域
- Contract Development and Manufacturing Organization (CDMO)、Contract Research Organization (CRO)、FRET and TR-FRET Substrates、cGMP Peptide Manufacturing、Regulatory Support、APIs、Custom Peptides、Catalog Peptide、Project Management、Generic Peptides、Cosmetic Peptides、Oligonucleotides、Neoantigens、Pepitde-Oligonucleotide Conjugates、Peptide Chelates、Stapled Pepitdes、Peptide Macrocycles、PEGylation、US Manufacturing、Semaglutide和tirzapetide
地点
CPC Scientific Inc.员工
动态
-
?? New White Paper Alert! ?? We're excited to share our latest white paper on Peptide Receptor Radionuclide Therapy (PRRT), a promising targeted treatment approach for cancer. PRRT leverages the power of peptides to deliver cytotoxic radiation directly to receptors overexpressed on cancer cells, offering key advantages such as: ?? Small size, favorable pharmacokinetics ?? High binding affinity and low toxicity ?? Minimal off-target effects This paper dives into the potential of PSMA (Prostate-Specific Membrane Antigen) as a target for prostate cancer, where it's overexpressed up to 1000-fold compared to normal tissue. PSMA’s transmembrane conformation makes it particularly effective for therapeutic internalization. We also showcase a successful case study on the manufacturing process of DOTAGA-labeled urea-based peptide PSMA inhibitor, achieved in just 10 months, from process development to GMP manufacturing at a multigram scale. Highlights include: ? Optimization and selection of synthesis strategy ? 85-90% crude yield (>98% final purity) ? Multi-gram R&D and CGMP synthesis in 10 months To read the full paper and learn more about this exciting cancer therapy approach, click here: https://lnkd.in/g_2MjtDe #PeptideTherapy #PRRT #CancerTreatment #PSMA #Biotech #RadionuclideTherapy #peptides #CDMO #peptidesynthesis
-
?? Day 1 at NextGen Biomed — We are excited to return to NextGen Biomed by Oxford Global this week (March 12-14) and are proud to be a Silver Sponsor! It’s a pleasure to be part of this dynamic event, where we have the opportunity to reconnect with industry leaders in peptide and oligo therapeutics here in London. ?? Meet Our Team at Booth 43 Don’t miss the opportunity to meet our team, including Tim Nieters, Sheri Ambriz, Joseph Denby, and Clàudia Badia i Lopez. They are eager to share our latest advancements and discuss how we’re pushing the boundaries of scientific discovery in the peptide and oligo therapeutics field. ?? Don’t miss the talk! Join us on March 13th at 12 PM, when Joseph Denby takes the stage to present "Green Approaches to Peptide API and Peptide-Oligonucleotide Conjugate (POC) Manufacturing." In this session, we'll explore sustainable methods in peptide and POC production, showing how greener processes can enhance efficiency and maintain high-quality standards. We’d love to chat about how CPC Scientific Inc. is driving innovation and sustainability in the peptide and oligo space! Schedule a meeting with us: https://lnkd.in/ghYqgu5E NextGen Biomed by Oxford Global #NextGenBiomed #CPCScientific #SilverSponsor #BiotechInnovation #PeptideManufacturing #Sustainability #LifeSciences #Networking #Innovation #GreenChemistry
-
-
Our team members, Sheri and Joseph, had a fantastic time at RNA Leaders EU 2025! It was great to connect with industry leaders, exchange insights, and explore the latest advancements in Oligonucleotide and Peptide therapeutics. A big thank you to the organizers and everyone we had the pleasure of meeting—looking forward to continuing these exciting conversations! RNA Leaders #RNALeaders #Biotech #Innovation #RNALeadersEU #CPCScientific #Oligo #Peptides #Oligonucleotide #BusinessDevelopment
-
-
?? New White Paper on RP-182 Analog Synthesis for Cancer Immunotherapy We are excited to share our latest white paper, a collaboration with Juan Marugan, Udo Rudloff, and Sitanshu S. Singh at the NIH and NCI. (Molecular Cancer Therapeutics, 2024, 23, 12, 1827-1841). The focus of this work is on the synthesis of cyclized RP-182 analogs for advancing cancer immunotherapy. RP-182 has shown promising potential in reprogramming immune-suppressive tumor-associated macrophages (TAMs), but its instability has hindered its clinical use. In this study, we explore how combining solid-phase peptide synthesis (SPPS) with click chemistry (SPAAC) enhances the stability and receptor-binding activity of RP-182 analogs through macrocyclization. Key Synthesis Insights: ?? Head-to-tail cyclization: For peptides longer than 10 amino acids, head-to-tail cyclization reactions often face slow reaction rates and increased side reactions. To address this, BCN (bicyclo[6.1.0]nonyne) was chosen for the click cyclization, paired with copper, to accelerate the reaction rate significantly. ?? Liquid-phase cyclization challenges: Liquid-phase cyclization often presents challenges like intermolecular side reactions and polymerization at higher concentrations. By combining SPPS with SPAAC, we effectively overcame these challenges, improving reaction efficiency and peptide yield. This collaboration sets the foundation for developing more effective peptide-based therapeutics aimed at targeting challenging cancers. ?? Read the full white paper to dive into the synthesis details and its implications for immunotherapy development. ?? Read Here: https://lnkd.in/gpam9AsX #CancerImmunotherapy #PeptideSynthesis #Macrocyclization #ClickChemistry #SPPS #PharmaceuticalResearch #InnovationInHealthcare #Peptides #CDMO #CMO #Cancer
-
-
On World Obesity Day, CPC Scientific Inc. joins the global effort to raise awareness of obesity and its impact on health. As a leading peptide and oligo CRDMO, we support innovation in obesity treatment through high-quality peptide APIs. At CPC Scientific Inc., we specialize in producing generic peptide APIs in GMP-compliant facilities, supporting drug development from discovery to commercial manufacturing. We provide: ? High-quality peptide APIs ? Comprehensive regulatory support, including DMF preparation & submission ? Seamless pathways for ANDA & NDA submissions Obesity is a growing health challenge, but scientific advancements can drive change. Let’s work together for a healthier future! Contact us: https://lnkd.in/e5pXSFeh #WorldObesityDay #HealthInnovation #CPCScientific #PeptideAPIs #Obesity
-
-
We are thrilled to be part of TIDES Asia 2025 in Kyoto, Japan! At Booth 3, we’ve been showcasing our expertise in synthetic GMP peptides, oligonucleotides, and peptide-oligonucleotide conjugates (POCs)—and there’s still time to connect! Meet Erin Wu, Manager of International Business Development, before the event wraps up! She’s available today to discuss how CPC Scientific can support your R&D efforts. Don’t miss this last opportunity to explore potential collaborations! To learn more: https://lnkd.in/gtRTuakV ?? Location: Kyoto, Japan ? Dates: February 26th - 28th ?? Booth: 3 We look forward to meeting you—see you soon! Informa Connect #TIDESAsia2025 #CPCScientific #SyntheticPeptides #Oligonucleotides #GMPPeptides #DrugDiscovery #Biotech #Pharmaceuticals #Innovation #KyotoJapan #LifeSciences
-
-
?? New White Paper: Green Synthesis of Goserelin Impurity E ?? We are excited to share the second installment of our Minimal Protection Group Strategies for SPPS series! In Part 1, we explored the removal of sidechain protection on hydroxy-bearing amino acids (like serine, threonine, tyrosine, and hydroxyproline) to improve atom economy and eliminate hazardous solvents. Download the full white paper here: ?? https://lnkd.in/gPs_sfjS In Part 2, we take things a step further by applying this approach to more challenging amino acids—histidine, tryptophan, and arginine. This new case study demonstrates how we successfully synthesized a Goserelin peptide API impurity using a convergent peptide fragment strategy. By eliminating the need for TFA and diethyl ether, we were able to streamline the synthesis process while maintaining a greener, more efficient methodology. ?? This work advances our commitment to sustainability in peptide synthesis and demonstrates the power of minimizing protection group use without compromising on quality. Read the full white paper to learn more about this innovative approach! #PeptideSynthesis #GreenChemistry #SustainableManufacturing #DrugDevelopment #GreenChemistry #Innovation #PharmaceuticalIndustry #SPPS #Goserelin #MinimalProtection #CDMO #CMO #Peptides
-
-
We’re thrilled to be a Silver Sponsor at NextGen Biomed, where innovation meets the future of life sciences! Join CPC Scientific Inc. on March 13th at 12 PM, as Joseph Denby takes the stage to discuss "Green Approaches to Peptide API and Peptide-Oligonucleotide Conjugate (POC) Manufacturing." Sustainability in peptide and POC production is more important than ever, and we’re excited to share insights on how greener processes can drive efficiency without compromising quality. Looking forward to great conversations and new connections—see you there! Schedule a meeting with us: https://lnkd.in/ghYqgu5E NextGen Biomed by Oxford Global #NGB2025 #PeptideManufacturing #DrugDevelopment #Peptide #Oligonucleotide #NextGenBiomed #Sustainability #Peptides #GreenChemistry #Innovation #CPCScientific
-
-
One week to go, please feel free to visit us to talk about your peptide/ oligo needs at Booth No 3 at TIDES Asia Event during Feb 26th to 28th.
We are thrilled to announce that CPC Scientific Inc. will be attending TIDES Asia 2025 in Kyoto, Japan, from February 26th to 28th! With over 20 years of experience, we are proud to be the preferred partner for top pharmaceutical and biotechnology companies, as well as respected universities worldwide. At Booth 3, we’ll be showcasing our expertise in synthetic GMP peptides, oligonucleotides, and peptide-oligonucleotide conjugates (POCs). Meet Erin Wu, Manager of International Business Development, who will be at the booth to discuss how CPC Scientific can support your R&D efforts. This is a great opportunity to connect and explore collaboration opportunities. ?? Location: Kyoto, Japan ? Dates: February 26th - 28th ?? Booth: 3 We look forward to seeing you in Kyoto, Japan! Informa Connect #TIDESAsia2025 #CPCScientific #SyntheticPeptides #Oligonucleotides #GMPPeptides #DrugDiscovery #Biotech #Pharmaceuticals #Innovation #KyotoJapan #LifeSciences
-